Toward personalized immunotherapy for non-hodgkin lymphoma targeting the idiotypic immunoglobulin

BioDrugs

Volumn 19, Issue 5, 2005, Pages 289-297

  Armstrong, Anne C ^a   Cheadle, Eleanor J ^a   Hawkins, Robert E ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CELL ADHESION MOLECULE; DENDRITIC CELL VACCINE; DNA VACCINE; IDIOTYPIC ANTIBODY; IDIOTYPIC DNA; IDIOTYPIC PROTEIN; KEYHOLE LIMPET HEMOCYANIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOLOGY; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN GENE; IMMUNOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; LYMPHOMA, B-CELL; VACCINES, DNA;

EID: 26444567732     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200519050-00002     Document Type: Review

References (80)

1. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13 (1): 140-7
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20 (5 Suppl. 5): 75-88
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16 (8): 2825-33
4. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96
5. Zarling AL, Johnson JG, Hoffman RW, et al. Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells. J Immunol 1999; 162 (9): 5197-204
6. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999; 170: 85-100
7. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999; 17: 739-79
8. Zhou D, Blum JS. Presentation of cytosolic antigens via MHC class II molecules. Immunol Res 2004; 30 (3): 279-90
9. Bosselut R. CD4/CD8-lineage differentiation in the thymus: from nuclear effectors to membrane signals. Nat Rev Immunol 2004; 4 (7): 529-40
10. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified spleno-cytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165 (2): 302-19
11. Dorfman DM, Schultze JL, Shahsafaei A, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997; 90 (11): 4297-306
12. Shamash J, Davies DC, Salam A, et al. Induction of CD80 expression in low-grade B cell lymphoma: a potential immunotherapeutic target. Leukemia 1995; 9 (8): 1349-52
13. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65 (6): 1349-63
14. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 1985; 312 (26): 1658-65
15. Cleary ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 1986; 44 (1): 97-106
16. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines: relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994; 153 (10): 4775-87
17. George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987; 138 (2): 628-34
18. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma: combination of idiotype immunization and cyclophosphamide. J Immunol 1988; 141 (9): 3227-33
19. Campbell MJ, Esserman L, Byars NE, et al. Development of a new therapeutic approach to B cell malignancy: the induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol 1989; 4 (4): 251-70
20. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179 (2): 523-32
21. Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139 (8): 2825-33
22. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327 (17): 1209-15
23. Nelson EL, Li X, Hsu FJ, et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996; 88 (2): 580-9
24. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 1997; 89 (9): 3129-35
25. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362 (6422): 755-8
26. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5 (10): 1171-7
27. Bendandi M, Kwak LW. Translational development of patient specific vaccination for follicular lymphoma. Haematologica 1999; 84 (S): 70-2
28. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356 (6365): 152-4
29. Apostolopoulos V, Plebanski M. The evolution of DNA vaccines. Curr Opin Mol Ther 2000; 2 (4): 441-7
30. Amici A, Smorlesi A, Noce G, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 2000; 7 (8): 703-6
31. Song K, Chang Y, Prud'homme GJ. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 2000; 7 (18): 1527-35
32. Song K, Chang Y, Prud'homme GJ. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther 2000; 7 (6): 481-92
33. Cesco-Gaspere M, Benvenuti F, Burrone OR. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies. Cancer Immunol Immunother 2005; 54 (4): 351-8
34. Hawkins RE, Zhu D, Ovecka M, et al. Idiotypic vaccination against human B-cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 1994; 83 (11): 3279-88
35. Hawkins RE, Russell SJ, Marcus R, et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach: CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther 1997; 8 (10): 1287-99
36. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2 (9): 1038-41
37. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4 (11): 1281-6
38. Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62 (20): 5845-52
39. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351 (9112): 1320-5
40. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178 (1): 92-100
41. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282 (5388): 476-80
42. Gramzinski RA, Millan CL, Obaldia N, et al. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med 1998; 4 (2): 109-18
43. Wang R, Epstein J, Baraceros FM, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 2001; 98 (19): 10817-22
44. Neumann E, Schaefer-Ridder M, Wang Y, et al. Gene transfer into mouse lyoma cells by electroporation in high electric fields. Embo J 1982; 1 (7): 841-5
45. Muramatsu T, Nakamura A, Park HM. In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals. Int J Mol Med 1998; 1 (1): 55-62
46. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96 (8): 4262-7
47. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999; 96 (11): 6417-22
48. Timmerman JM, Caspar CB, Lambert SL, et al. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001; 97 (5): 1370-7
49. Armstrong AC, Dermime S, Allinson CG, et al. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002; 168 (8): 3983-91
50. Hodge JW, McLaughlin JP, Kantor JA, et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997; 15 (6-7): 759-68
51. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18 (23): 3964-73
52. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002; 62 (20): 5770-7
53. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24 (3): 605-10
54. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2 (1): 52-8
55. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99 (5): 1517-26
56. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193 (2): 233-8
57. Pulendran B. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res 2004; 29 (1-3): 187-96
58. Serody JS, Collins EJ, Tisch RM, et al. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 2000; 164 (9): 4961-7
59. Wang M, Chen PW, Bronte V, et al. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol 1995; 18 (3): 139-46
60. Abrams SI, Hodge JW, McLaughlin JP, et al. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anti-cancer vaccine. J Immunother 1997; 20 (1): 48-59
61. Bristol JA, Schlom J, Abrams SI. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lympho-cytes following in vivo adoptive transfer. Cell Immunol 1999; 194 (1): 78-89
62. Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000; 13 (2): 265-76
63. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330 (17): 1185-91
64. Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72 (8): 1399-402
65. Bourgault I, Gomez A, Gomard E, et al. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 1991; 84 (3): 501-7
66. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345 (8941): 9-13
67. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004; 101 Suppl. 2: 14639-45
68. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152 (1): 163-75
69. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50 (3-4): 213-9
70. Muller G, Muller A, Jonuleit H, et al. Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches. J Invest Dermatol 2000; 114 (1): 142-9
71. Harig S, Witzens M, Krackhardt AM, et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 2001; 98 (10): 2999-3005
72. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999; 162 (8): 4790-5
73. Selmayr M, Menzel H, Kremer JP, et al. B-cell lymphoma idiotypes chimerised by gene targeting can induce tumor immunity. Cancer Gene Ther 2000; 7 (3): 501-6
74. Biragyn A, Tani K, Grimm MC, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17 (3): 253-8
75. Haimovich J, Kukulansky T, Weissman B, et al. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice. Cancer Immunol Immunother 1999; 47 (6): 330-6
76. Kwak LW, Young HA, Pennington RW, et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996; 93 (20): 10972-7
77. Lauritzsen GF, Bogen B. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993; 148 (1): 177-88
78. Lundin KU, Hofgaard PO, Omholt H, et al. Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood 2003; 102 (2): 605-12
79. Armstrong AC, Dermime S, Mulryan K, et al. Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother 2004; 27 (3): 227-31
80. Thistlethwaite F, Mansoor W, Gilham DE, et al. Engineering T-cells with anti-body-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther 2005; 7 (1): 48-55